Previous Article | Next Article 
Journal of Clinical Microbiology, September 2000, p. 3513-3514, Vol. 38, No. 9
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Brevibacterium casei Sepsis in an
18-Year-Old Female with AIDS
P.
Brazzola,1
R.
Zbinden,2
C.
Rudin,1
U. B.
Schaad,1 and
U.
Heininger1,*
University Children's Hospital, CH-4005
Basel,1 and Department of Medical
Microbiology, University of Zurich, CH-8028
Zurich,2 Switzerland
Received 6 March 2000/Returned for modification 28 April
2000/Accepted 11 July 2000
 |
ABSTRACT |
Brevibacterium sp. was isolated from the blood of an
acutely ill 18-year-old female with AIDS. The isolate was identified as
Brevibacterium casei by use of carbohydrate assimilation
tests. Treatment was successful with intravenously administered
ciprofloxacin. To our knowledge, this is the first report of sepsis
caused by B. casei in a human immunodeficiency
virus-infected patient.
 |
CASE REPORT |
An 18-year-old female from Ruanda,
adopted by Swiss foster parents at 5 years of age, was diagnosed as
being infected with human immunodeficiency virus type 1 (HIV-1) in
1991. She suffered a complicated course during subsequent years with
oral hairy leukoplakia in 1992, neutropenia and anemia in 1993, herpes
zoster in 1995, and severe wasting due to untreatable recurrent
episodes of vomiting and diarrhea thereafter. A Port-a-cath system
(Pharmacia Upjohn Hospital Group, Dübendorf, Switzerland) was
implanted in 1997 for partial parenteral nutrition. Unfortunately, the
Port-a-cath had to be exchanged twice due to catheter infection caused
by coagulase-negative staphylococci (CoNS) and thrombosis in July and
October 1997.
In April 1999, the patient presented to a primary-care hospital with
high fever that had persisted for 10 days and marked dehydration. CoNS
were isolated from blood culture. Fever persisted despite antibiotic
treatment with amoxicillin-clavulanate (1.2 g three times a day), and
the patient was transferred to our center. One set of peripheral
cultures as well as blood cultures (Bactec; Becton Dickinson
Microbiology Systems, Cockeysville, Md.) from the Port-a-cath taken by
us on admission grew gram-positive rods after 48 h. Overnight
subcultures on Columbia blood agar (Becton Dickinson) revealed whitish
colonies, which were identified as Brevibacterium sp. by use
of the commercially available API Coryne system (version 2.0;
bioMérieux, Marcy-l'Etoile, France), which has a 94.2%
probability of identification and a T index of 0.94 (code 4112004).
Tests for pyrrolidonyl arylamidase, alcaline phosphatase, alpha
glucosidase, hydrolysis of gelatine, and catalase were positive, but
acid was not produced from glucose and other carbohydrates. The
Port-a-cath was removed, and antibiotic treatment was changed to
intravenously administered ciprofloxacin (400 mg twice a day). Our
patient's clinical condition improved rapidly, and fever resolved within 2 days. After treatment for 14 days, a new Port-a-cath was
implanted and the patient was dismissed shortly thereafter.
Microbiology.
Patients with indwelling central venous
catheters are at high risk of acquiring bloodstream infections. Among a
wide range of causative agents, Brevibacterium spp. are
rarely found (1). Here we report isolation of
Brevibacterium casei from a Port-a-cath system and from
peripheral blood in an acutely ill patient with AIDS and wasting syndrome.
The patient's isolate was sent to the Department of Medical
Microbiology in Zurich, Switzerland, for further identification. The
gram-positive short coryneform rods formed whitish gray colonies with a
distinctive cheese-like smell typical of Brevibacterium spp., and their identity was confirmed by conventional tests, i.e.,
production of methanethiol and hydrolysis of casein and tyrosine
(2). The isolate was identified as B. casei by
use of carbohydrate assimilation tests previously described
(3). Briefly, 3 × 108 bacterial cells in 1 ml of 0.85% NaCl were transferred to 15 ml of AUX medium
(bioMérieux), and 300 µl of this suspension was transferred
into each cupule of the API 50CH system (bioMérieux) and
incubated at 37°C for 48 h before assimilation tests were read.
Opaque cupules indicated a positive reaction, i.e., bacterial growth.
Cupules without bacterial growth remained clear (negative reaction).
Based on the assimilation of D-arabinose,
N-acetylglucosamine, maltose, saccharose, trehalose,
D-turanose, and L-fucose and lack of growth
with mannitol and D-arabitol, a clear distinction from other Brevibacterium spp. could be made (3).
Furthermore, the analysis of cellular fatty acids revealed 9.5%
i-C15:0, 47.5% a-C15:0, 5%
i-C16:0, 0.5% C16:0, 2.4%
i-C17:0, and 33.5% a-C17:0; this composition
is in line with those published by Funke and Carlotti (3).
MICs were determined by the E-test (AB Biodisk, Solna, Sweden)
procedure on Mueller-Hinton agar (Becton Dickinson). The plates
were
swabbed with an inoculum in 0.85% NaCl with a turbidity equal
to a 0.5 McFarland standard. Plates were incubated at 35°C for
24 h at
ambient air temperature. The MICs of amoxicillin-clavulanic
acid,
ampicillin, ciprofloxacin, clindamycin, erythromycin, gentamicin,
penicillin, teicoplanin, tetracycline, and vancomycin were 1.5
mg/ml, 2 mg/liter, 0.75 mg/liter, 1.5 mg/liter, 0.5 mg/liter,
0.75 mg/liter, 1 mg/liter, 0.25 mg/liter, 0.5 mg/liter, and 0.38
mg/liter, respectively.
Interpretative breakpoints are not available
for coryneform bacteria,
but our results of decreased susceptibilities
to beta-lactams are in
line with the data of Funke et al. (
4).
We assume from the
clinical improvement of our patient that the
isolate was susceptible to
ciprofloxacin, which has a MIC of 0.75
mg/liter.
Brevibacteria are catalase-positive, non-spore-forming, nonmotile,
aerobic gram-positive rods. They can be found in raw milk
and
surface-ripened cheese as well as on human skin and in animal
sources.
The genus
Brevibacterium currently consists of six species,
namely,
B. linens,
B. casei,
B. epidermidis,
B. iodinum,
B. mcbrellneri,
and
B. otitidis (
5). Despite earlier reports of
Brevibacterium spp. isolated from humans (
7,
9,
10), they had been considered
a nonpathogenic species. In 1994, Gruner and collaborators found
that of 41 strains in the collection of
the Bacteriology Reference
Laboratory of the Centers for Disease
Control and Prevention,
which were formerly assigned to CDC groups B-1
and B-3, 22 were
in fact
B. casei and most of them were
isolated from blood cultures
(
6). Other reports followed,
and it is now accepted that
B. casei is by far the most
frequently isolated
Brevibacterium from
otherwise sterile
human sites (
1,
3,
6,
11). Although
B. casei can
cause a variety of infections, such as sepsis, meningitis,
cholangitis,
salpingitis, and peritonitis, most isolates derive
from blood cultures,
as exemplified by 19 of 42 isolates collected
by Funke and Carlotti
from various laboratories in Europe and
Ottawa, Canada (
3).
Patients with indwelling central venous catheters are at high risk of
acquiring bloodstream infections. Among a wide range
of causative
agents, CoNS,
Staphylococcus aureus, gram-negative
rods, and
Candida species are most frequently isolated (
8).
However, a variety of unusual pathogens may also be encountered,
especially in immunocompromised patients. Among these,
Brevibacterium spp. are rarely found (
1,
11). The
observation of
B. casei sepsis in an AIDS patient is new and
adds this species to the
list of unusual pathogens complicating HIV
infection. Since brevibacteria
may easily be confused with apathogenic
corynebacteria, physicians
treating patients with HIV infection and
other immunocompromising
conditions should be aware of this bacterial
genus as a potential
cause of invasive
infection.
 |
ACKNOWLEDGMENTS |
We acknowledge technical laboratory support by Edda Williamson and
Marianne Fahrner, University Children's Hospital Basel, and by
Elisabeth Huf, Department of Medical Microbiology, University of Zurich.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University
Children's Hospital (UKBB), PO Box, CH-4005 Basel, Switzerland. Phone:
41-61-685 6565. Fax: 41-61-685 6012. E-mail:
Ulrich.Heininger{at}unibas.ch.
 |
REFERENCES |
| 1.
|
Castagnola, E.,
M. Conte,
P. Venzano,
A. Garaventa,
C. Viscoli,
M. A. Barretta,
L. Pescetto,
L. Tasso,
M. Nantron,
C. Milanaccio, and R. Giacchino.
1997.
Broviac catheter-related bacteraemias due to unusual pathogens in children with cancer: case reports with literature review.
J. Infect.
34:215-218[CrossRef][Medline].
|
| 2.
|
Früh, M.,
A. von Graevenitz, and G. Funke.
1998.
Use of second-line biochemical and susceptibility tests for the differential identification of coryneform bacteria.
Clin. Microbiol. Infect.
4:323-328.
|
| 3.
|
Funke, G., and A. Carlotti.
1994.
Differentiation of Brevibacterium spp. encountered in clinical specimens.
J. Clin. Microbiol.
32:1729-1732[Abstract/Free Full Text].
|
| 4.
|
Funke, G.,
V. Pünter, and A. von Graevenitz.
1996.
Antimicrobial susceptibility patterns of some recently established coryneform bacteria.
Antimicrob. Agents Chemother.
40:2874-2878[Abstract].
|
| 5.
|
Funke, G., and K. A. Bernard.
1999.
Coryneform gram-positive rods, p. 319-345.
In
P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
|
| 6.
|
Gruner, E.,
A. G. Steigerwalt,
D. G. Hollis,
R. S. Weyant,
R. E. Weaver,
C. W. Moss,
M. Daneshvar,
J. M. Brown, and D. J. Brenner.
1994.
Human infections caused by Brevibacterium casei, formerly CDC groups B-1 and B-3.
J. Clin. Microbiol.
32:1511-1518[Abstract/Free Full Text].
|
| 7.
|
McCaughey, C., and N. N. Damani.
1991.
Central venous line infection caused by Brevibacterium epidermidis.
J. Infect.
23:211-212[CrossRef][Medline].
|
| 8.
|
Mueller, B. U.,
J. Skelton,
D. P. E. Callender,
D. Marshall,
J. Gress,
D. Longo,
J. Norton,
M. Rubin,
D. Venzon, and P. A. Pizzo.
1992.
A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients.
J. Clin. Oncol.
10:1943-1948[Abstract].
|
| 9.
|
Neumeister, B.,
T. Mandel,
E. Gruner, and G. E. Pfyffer.
1993.
Brevibacterium species as a cause of osteomyelitis in a neonate.
Infection
21:177-178[CrossRef][Medline].
|
| 10.
|
Pitcher, D. G., and H. Malnick.
1984.
Identification of Brevibacterium from clinical sources.
J. Clin. Pathol.
37:1395-1398[Abstract/Free Full Text].
|
| 11.
|
Reinert, R. R.,
N. Schnitzler,
G. Haase,
R. Lütticken,
U. Fabry,
K. P. Schaal, and G. Funke.
1995.
Recurrent bacteremia due to Brevibacterium casei in an immunocompromised patient.
Eur. J. Clin. Microbiol. Infect. Dis.
14:1082-1085[CrossRef][Medline].
|
Journal of Clinical Microbiology, September 2000, p. 3513-3514, Vol. 38, No. 9
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Fraser, M. A., Girling, S. J.
(2009). Bacterial carriage of computer keyboards in veterinary practices in Scotland. Vet Rec.
165: 26-27
[Full Text]
-
Hillesland, H., Read, A., Subhadra, B., Hurwitz, I., McKelvey, R., Ghosh, K., Das, P., Durvasula, R.
(2008). Identification of Aerobic Gut Bacteria from the Kala Azar Vector, Phlebotomus argentipes: A Platform for Potential Paratransgenic Manipulation of Sand Flies. Am J Trop Med Hyg
79: 881-886
[Abstract]
[Full Text]
-
Griffin, D. W.
(2007). Atmospheric Movement of Microorganisms in Clouds of Desert Dust and Implications for Human Health. Clin. Microbiol. Rev.
20: 459-477
[Abstract]
[Full Text]
-
Wauters, G., Haase, G., Avesani, V., Charlier, J., Janssens, M., Van Broeck, J., Delmee, M.
(2004). Identification of a Novel Brevibacterium Species Isolated from Humans and Description of Brevibacterium sanguinis sp. nov.. J. Clin. Microbiol.
42: 2829-2832
[Abstract]
[Full Text]